

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement is for information purposes only and does not constitute an invitation or solicitation of an offer to acquire, purchase or subscribe for securities or an invitation to enter into an agreement to do any such things, nor is it calculated to invite any offer to acquire, purchase or subscribe for any securities.*

*This announcement is not for distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement and the information herein does not constitute or form a part of any offer or solicitation to purchase, subscribe or sell securities in the United States. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the “**Securities Act**”), or the securities laws of any state of the United States or other jurisdiction. The securities referred to herein are being offered and sold outside the United States in reliance on Regulation S under the Securities Act (the “**Regulation S**”) and may not be offered or sold within the United States absent registration or an applicable exemption from registration under the Securities Act. No public offering of the securities referred to herein will be made in the United States or in any other jurisdiction where such an offering is restricted or prohibited. No money, securities or other consideration is being solicited by this announcement or the information contained herein and, if sent in response to this announcement or the information contained herein, will not be accepted.*



**LUYE PHARMA GROUP LTD.**

**绿叶制药集团有限公司**

*(Incorporated in Bermuda with limited liability)*

**(Stock Code: 02186)**

**(Bond Stock Code: 05818)**

**COMPLETION OF ISSUE OF US\$180,000,000  
5.25 PER CENT. CONVERTIBLE BONDS DUE 2031**

**Sole Global Coordinator, Sole Overall Coordinator,  
Sole Bookrunner and Sole Dealer Manager**



Reference is made to the announcements of Luye Pharma Group Ltd. (the “**Company**”) dated 3 June 2026 and 4 June 2026 in relation to the Concurrent Repurchase and issue of the Bonds (the “**Announcements**”). Capitalised terms used in this announcement shall have the same meanings as those defined in the Announcements unless otherwise stated.

## **COMPLETION OF THE ISSUE OF US\$180,000,000 5.25 PER CENT. CONVERTIBLE BONDS DUE 2031 BY THE COMPANY**

The Board announces that all the conditions precedent to the issue of the Bonds as set out in the Subscription Agreement have been satisfied and completion of the subscription and issuance of the Bonds in an aggregate principal amount of US\$180,000,000 took place on 10 June 2026. The Bonds were listed on the Vienna Stock Exchange on 10 June 2026.

To the best of the Directors’ knowledge, information and belief, having made all reasonable enquiries, as at the date of this announcement, each of the initial placees (and their respective ultimate beneficial owners) is a third party independent of the Company and is not a connected person of the Company.

The initial Conversion Price is HK\$2.71 per Conversion Share, which represents: (a) a premium of approximately 24.9 per cent. over the closing price of HK\$2.170 as quoted on the Stock Exchange on 3 June 2026 (being the trading day on which the Subscription Agreement was signed); and (b) a premium of approximately 24.1 per cent. over HK\$2.184, being the average of the closing price per Share as quoted on the Stock Exchange for the last five consecutive trading days up to and including 2 June 2026. Approval for the listing of, and permission to deal in, the Conversion Shares, has been granted by the Stock Exchange.

The Company currently intends to use the net proceeds of approximately US\$177.2 million from the Bonds to refinance existing indebtedness (including without limitation, for funding the Concurrent Repurchase) and for general corporate purposes, as disclosed in the Announcements.

As of the date of this announcement, the Concurrent Repurchase is being processed and the Company will issue a further announcement on its completion as and when appropriate.

By Order of the Board  
**LUYE PHARMA GROUP LTD.**  
**Liu Dian Bo**  
*Chairman*

Hong Kong, 11 June 2026

*As at the date of this announcement, the executive directors of the Company are Mr. LIU Dian Bo, Mr. YANG Rong Bing, Mr. YUAN Hui Xian and Ms. ZHU Yuan Yuan; the non-executive directors of the Company are Mr. SONG Rui Lin and Mr. HUANG Liming; and the independent non-executive directors of the Company are Mr. ZHANG Hua Qiao, Professor LO Yuk Lam, Mr. LEUNG Man Kit, Mr. CHOY Sze Chung Jojo and Ms. XIA Lian.*